Picture of NuVasive logo

NUVA — NuVasive News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedMid Cap

NuVasive Inc expected to post earnings of 49  cents a share - Earnings Preview

* NuVasive Inc  NUVA.OQ   NUVA.O  is expected to show a rise
in
quarterly revenue when it reports  results on February 23. 
    * The San Diego California-based  company is expected to
report  a
2.4% increase in revenue to $298.951 million from $291.81
million a year ago, according to the mean estimate from 15
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for NuVasive Inc is for
earnings of 49 cents per share. For the same quarter last year,
the company reported earnings of 59 cents per share.
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 7
"hold" and 2 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for NuVasive
Inc is
$60​, about 15.4% above​ its last closing price of $50.79. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  0.52        0.53       0.32      Missed  -40.1
 Jun. 30 2021  0.46        0.44       0.60      Beat    35
 Mar. 31 2021  0.36        0.35       0.37      Beat    5.9​
 Dec. 31 2020  0.55        0.55       0.59      Beat    6.4
 ​​Sep.        0.23        0.24       0.55      Beat    130.9
 30 2020                                                
 Jun. 30 2020  -0.40       -0.47      -0.40     Beat    15.6​
 Mar. 31 2020  0.38        0.41       0.48      Beat    17.3
 Dec. 31 2019  0.64        0.64       0.73      Beat    14.3
 This summary was machine generated February 22 at 03:05 GMT. 
All figures in US dollars  unless otherwise stated

Recent news on NuVasive

See all news